SCHEMBL15027204

SCHEMBL15027204

CCCCCC(CCCCC)CCOC(=O)CCCCCCCC(CCCCCCCC(=O)OCCC(CCCCC)CCCCC)C(=O)OCCCN1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ DGKA P23743 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ THRB P10828 4/20 0.41
▸ THRA P10827 2/20 0.41
▸ ESR1 P03372 2/20 0.39
▸ HRH2 P25021 4/20 0.38
▸ HRH1 P35367 4/20 0.38
▸ LMNA P02545 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ CHRM5 P08912 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ DRD4 P21917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17124001 1.00 ALDH1A1 (0.52) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL15027837 1.00 ALDH1A1 (0.52) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL15027372 1.00 ALDH1A1 (0.52) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL17123899 1.00 ALDH1A1 (0.52) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL24368823 0.99 L3MBTL1 (0.50) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL17123907 0.99 L3MBTL1 (0.50) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL15027947 0.99 L3MBTL1 (0.50) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL15027287 0.99 L3MBTL1 (0.50) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL15027416 0.99 L3MBTL1 (0.50) ALDH1A1L3MBTL1DGKAMAPTMAPK1
SCHEMBL17123991 0.99 L3MBTL1 (0.50) ALDH1A1L3MBTL1DGKAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230256098-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2023-08-17 — — US disclosed
US-20230256098-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2023-08-17 — — US disclosed
US-11679158-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-20 — — US disclosed
US-11679158-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-20 — — US disclosed
US-11633479-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2023-04-25 — — US disclosed
US-20220347302-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. 2022-11-03 — — US disclosed
US-20220125927-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2022-04-28 — — US disclosed
US-11246933-B1 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2022-02-15 — — US disclosed
US-11071784-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2021-07-27 — — US disclosed
US-10369226-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2019-08-06 — — US disclosed
US-20150306039-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS BANK OF AMERICA, N.A. 2015-10-29 — — US disclosed
US-20150306039-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS BANK OF AMERICA, N.A. 2015-10-29 — — US disclosed
US-20150273068-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2015-10-01 — — US disclosed
US-20150273068-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS BANK OF AMERICA, N.A. 2015-10-01 — — US disclosed
US-9061063-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2015-06-23 — — US disclosed
US-9061063-B2 Biodegradable lipids for the delivery of active agents ALNYLAM PHARMACEUTICALS, INC. (US) 2015-06-23 — — US disclosed
WO-2014089239-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS ALNYLAM PHARMACEUTICALS, INC. (US) 2014-06-12 — — WO disclosed
US-20130195920-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-01 — — US disclosed
US-20130195920-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-01 — — US disclosed
WO-2013086354-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11633479-B2 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-20130195920-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-20150273068-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-10369226-B2 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-20220347302-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-11246933-B1 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-11679158-B2 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-20230256098-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-20220125927-A1 BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-11071784-B2 Biodegradable lipids for the delivery of active agents LIPA, APOB, CETP ALDH1A1 3151/4885L3MBTL1 1228/4885DGKA 352/4885
US-20150306039-A1 IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS LIPA, NPC1L1, CETP ALDH1A1 2297/4885L3MBTL1 1408/4885DGKA 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback